Historically, FDA-approved CD3-based TCEs have been monovalent to the disease target until recently, with agents like Glofitamab (CD20-CD3 TCE with two CD20-binding Fabs) and thus have been largely limited to uniquely expressed antigens such as CD19
However, given the intense interest and enthusiasm about these drugs, experts believe that recommendations as to who should use them will change in the coming years
The duration of GLP-1 therapy varies significantly from person to person, with clinical data showing that sustained treatment often produces the best long-term weight loss results
15 14 13 12 11 10 9 8 7 6 5 -30 2 14 30 60 90 120 150 180 210 240 270 300 l 16- 15- i ,
The peptide proved effective across multiple delivery routes, demonstrating therapeutic flexibility
If you wish to become pregnant, you should stop using this medicine at least two months in advance